Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 143

1.

Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.

Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, Yimer G, Riedel KD, Janabi M, Aderaye G, Mugusi F, Bertilsson L, Aklillu E, Burhenne J.

PLoS One. 2013 Jul 5;8(7):e67946. doi: 10.1371/journal.pone.0067946. Print 2013.

PMID:
23861838
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.

Habtewold A, Amogne W, Makonnen E, Yimer G, Riedel KD, Ueda N, Worku A, Haefeli WE, Lindquist L, Aderaye G, Burhenne J, Aklillu E.

J Antimicrob Chemother. 2011 Oct;66(10):2350-61. doi: 10.1093/jac/dkr304. Epub 2011 Aug 16.

PMID:
21846671
[PubMed - indexed for MEDLINE]
Free Article
3.

Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.

Mukonzo JK, Okwera A, Nakasujja N, Luzze H, Sebuwufu D, Ogwal-Okeng J, Waako P, Gustafsson LL, Aklillu E.

BMC Infect Dis. 2013 Jun 4;13:261. doi: 10.1186/1471-2334-13-261.

PMID:
23734829
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study.

Yimer G, Amogne W, Habtewold A, Makonnen E, Ueda N, Suda A, Worku A, Haefeli WE, Burhenne J, Aderaye G, Lindquist L, Aklillu E.

Pharmacogenomics J. 2012 Dec;12(6):499-506. doi: 10.1038/tpj.2011.34. Epub 2011 Aug 23.

PMID:
21862974
[PubMed - indexed for MEDLINE]
5.

High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.

Swart M, Skelton M, Ren Y, Smith P, Takuva S, Dandara C.

Pharmacogenet Genomics. 2013 Aug;23(8):415-27. doi: 10.1097/FPC.0b013e328363176f.

PMID:
23778320
[PubMed - indexed for MEDLINE]
6.

Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients.

Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Burhenne J, Aklillu E.

Clin Pharmacol Ther. 2010 Nov;88(5):676-84. doi: 10.1038/clpt.2010.172. Epub 2010 Sep 29.

PMID:
20881953
[PubMed - indexed for MEDLINE]
7.

CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.

Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA.

AIDS. 2007 Oct 18;21(16):2191-9.

PMID:
18090046
[PubMed - indexed for MEDLINE]
8.

Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.

Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, Burhenne J, Aderaye G, Lindquist L, Makonnen E, Aklillu E.

PLoS One. 2011;6(12):e27810. doi: 10.1371/journal.pone.0027810. Epub 2011 Dec 6.

PMID:
22162992
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania.

Mugusi S, Ngaimisi E, Janabi M, Minzi O, Bakari M, Riedel KD, Burhenne J, Lindquist L, Mugusi F, Sandstrom E, Aklillu E.

PLoS One. 2012;7(7):e40180. doi: 10.1371/journal.pone.0040180. Epub 2012 Jul 11.

PMID:
22808112
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.

Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH.

Br J Clin Pharmacol. 2009 Apr;67(4):427-36. doi: 10.1111/j.1365-2125.2009.03368.x.

PMID:
19371316
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.

Elens L, Vandercam B, Yombi JC, Lison D, Wallemacq P, Haufroid V.

Pharmacogenomics. 2010 Sep;11(9):1223-34. doi: 10.2217/pgs.10.94.

PMID:
20860463
[PubMed - indexed for MEDLINE]
12.

Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.

Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, Ritchie MD, Zanger UM, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford D, Haas DW.

J Infect Dis. 2010 Sep 1;202(5):717-22. doi: 10.1086/655470.

PMID:
20662624
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.

Chen J, Sun J, Ma Q, Yao Y, Wang Z, Zhang L, Li L, Sun F, Lu H.

Ther Drug Monit. 2010 Oct;32(5):573-8. doi: 10.1097/FTD.0b013e3181ea953c.

PMID:
20625352
[PubMed - indexed for MEDLINE]
14.

Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.

Heil SG, van der Ende ME, Schenk PW, van der Heiden I, Lindemans J, Burger D, van Schaik RH.

Ther Drug Monit. 2012 Apr;34(2):153-9. doi: 10.1097/FTD.0b013e31824868f3.

PMID:
22354160
[PubMed - indexed for MEDLINE]
15.

Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients.

Habtewold A, Amogne W, Makonnen E, Yimer G, Nylén H, Riedel KD, Aderaye G, Bertilsson L, Burhenne J, Diczfalusy U, Aklillu E.

Pharmacogenomics J. 2013 Dec;13(6):484-9. doi: 10.1038/tpj.2012.46. Epub 2012 Oct 23.

PMID:
23089673
[PubMed - indexed for MEDLINE]
16.

Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.

Sukasem C, Cressey TR, Prapaithong P, Tawon Y, Pasomsub E, Srichunrusami C, Jantararoungtong T, Lallement M, Chantratita W.

Br J Clin Pharmacol. 2012 Dec;74(6):1005-12. doi: 10.1111/j.1365-2125.2012.04288.x.

PMID:
22471906
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.

Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Bertilsson L, Burhenne J, Aklillu E.

Clin Pharmacol Ther. 2011 Sep;90(3):406-13. doi: 10.1038/clpt.2011.129. Epub 2011 Aug 3.

PMID:
21814190
[PubMed - indexed for MEDLINE]
18.

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.

Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH.

AIDS. 2009 Oct 23;23(16):2101-6. doi: 10.1097/QAD.0b013e3283319908.

PMID:
19779319
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Sleep quality in efavirenz-treated Chinese HIV patients - comparing between GT and GG genotype of CYP2B6-516 G/T polymorphisms.

Lee SS, To KW, Lee MP, Wong NS, Chan DP, Li PC, Cheung SW, Chan RC.

Int J STD AIDS. 2014 Mar;25(3):193-200. doi: 10.1177/0956462413498581. Epub 2013 Jul 23.

PMID:
23970651
[PubMed - indexed for MEDLINE]
20.

Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.

Saitoh A, Fletcher CV, Brundage R, Alvero C, Fenton T, Hsia K, Spector SA.

J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):280-5.

PMID:
17356468
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk